BR112022019649A2 - Interação das proteínas sars-cov-2 com mecanismos moleculares e celulares de células hospedeiras e formulações para tratar o covid-19 - Google Patents

Interação das proteínas sars-cov-2 com mecanismos moleculares e celulares de células hospedeiras e formulações para tratar o covid-19

Info

Publication number
BR112022019649A2
BR112022019649A2 BR112022019649A BR112022019649A BR112022019649A2 BR 112022019649 A2 BR112022019649 A2 BR 112022019649A2 BR 112022019649 A BR112022019649 A BR 112022019649A BR 112022019649 A BR112022019649 A BR 112022019649A BR 112022019649 A2 BR112022019649 A2 BR 112022019649A2
Authority
BR
Brazil
Prior art keywords
covid
cov
sars
formulations
proteins
Prior art date
Application number
BR112022019649A
Other languages
English (en)
Inventor
Shreema Merchant Dr
PATEL Manit
Elaine Duncan Robin
Vishal Anant Jadhav Dr
Fernanda De Andrade Fernandes Maria
Original Assignee
Akseera Pharma Corp
Shreema Merchant Dr
PATEL Manit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akseera Pharma Corp, Shreema Merchant Dr, PATEL Manit filed Critical Akseera Pharma Corp
Publication of BR112022019649A2 publication Critical patent/BR112022019649A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

INTERAÇÃO DAS PROTEÍNAS SARS-COV-2 COM MECANISMOS MOLECULARES E CELULARES DE CÉLULAS HOSPEDEIRAS E FORMULAÇÕES PARA TRATAR O COVID-19. A presente invenção fornece composições farmacêuticas e métodos de tratamento de doenças infecciosas Covid-19. A presente invenção também fornece composições farmacêuticas e métodos de profilaxia ou tratamento profilático da doença infecciosa Covid-19. Os referidos métodos envolvem a administração de composições constituídas de uma quantidade terapeuticamente eficaz de canabidiol causando assim o aprimoramento/aumento da imunidade inata do paciente/mamífero/humano.
BR112022019649A 2020-03-29 2021-03-30 Interação das proteínas sars-cov-2 com mecanismos moleculares e celulares de células hospedeiras e formulações para tratar o covid-19 BR112022019649A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN202021013770 2020-03-29
IN202021030633 2020-07-18
IN202021054151 2020-12-12
PCT/IN2021/050325 WO2021199078A2 (en) 2020-03-29 2021-03-30 Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19.

Publications (1)

Publication Number Publication Date
BR112022019649A2 true BR112022019649A2 (pt) 2022-12-27

Family

ID=77927896

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019649A BR112022019649A2 (pt) 2020-03-29 2021-03-30 Interação das proteínas sars-cov-2 com mecanismos moleculares e celulares de células hospedeiras e formulações para tratar o covid-19

Country Status (8)

Country Link
EP (1) EP4126913A2 (pt)
JP (1) JP2023528561A (pt)
CN (1) CN115968375A (pt)
AU (1) AU2021247269A1 (pt)
BR (1) BR112022019649A2 (pt)
IL (1) IL296892A (pt)
MX (1) MX2022012165A (pt)
WO (1) WO2021199078A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115531315B (zh) * 2022-12-05 2023-04-07 上海惠盾因泰生物科技有限公司 重组人干扰素λ1鼻喷雾剂及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1652766A (zh) * 2002-03-18 2005-08-10 免疫力药品有限公司 间苯二酚和大麻素的局部制剂及其施用方法
EP1559423A1 (en) * 2004-02-02 2005-08-03 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
WO2012012498A2 (en) * 2010-07-20 2012-01-26 Pulmatrix, Inc. Use of trp channel agonists to treat infections
NL2009671C2 (en) * 2012-10-19 2014-04-23 Fytagoras B V New antiviral use for acidic cannabinoids.
US10456435B2 (en) * 2015-07-15 2019-10-29 Christopher A. MCELVANY Topical antiviral formulations and methods of using the same
WO2020257588A1 (en) * 2019-06-20 2020-12-24 Shaman Naturals, Llc Compositions for preventing and treating viral infections
JP2023516284A (ja) * 2020-02-19 2023-04-19 マーチャント，シュリーマ カンナビジオールの組成物および治療的使用
CN111686095A (zh) * 2020-07-24 2020-09-22 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途

Also Published As

Publication number Publication date
AU2021247269A1 (en) 2022-12-01
EP4126913A2 (en) 2023-02-08
WO2021199078A3 (en) 2021-12-09
CN115968375A (zh) 2023-04-14
IL296892A (en) 2022-12-01
JP2023528561A (ja) 2023-07-05
WO2021199078A2 (en) 2021-10-07
MX2022012165A (es) 2023-01-24

Similar Documents

Publication Publication Date Title
Hodge Osteopathic lymphatic pump techniques to enhance immunity and treat pneumonia
Degli Agosti et al. Effectiveness of a Short‐Term Treatment of Oxygen‐Ozone Therapy into Healing in a Posttraumatic Wound
Douglas Re-thinking lactation-related nipple pain and damage
Kucharzewski et al. Topical treatment of nonhealing venous leg ulcer with propolis ointment
BR112021023340A2 (pt) Composições compreendendo uma linhagem bacteriana de lactobacillus paracasei e ácido hialurônico e uso do mesmo para o tratamento da pele
BR112021022283A2 (pt) Novas endolisinas de gardnerella e usos das mesmas
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112022019649A2 (pt) Interação das proteínas sars-cov-2 com mecanismos moleculares e celulares de células hospedeiras e formulações para tratar o covid-19
RU2668827C2 (ru) Топическая противомикробная дерматологическая композиция
CO2022015966A2 (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
BR112023024701A2 (pt) Métodos de tratamento de doenças do fígado
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante
BR112022021284A2 (pt) Composição farmacêutica, seu uso para tratar ou prevenir um câncer induzido pelo vírus do papiloma humano, e combinação
Avijgan et al. Aloe vera gel as a traditional and complementary method for chronic skin burn: A case report
Singh et al. Leg ulceration in sickle cell disease: an early and visible sign of end-organ disease
BR112017022390A2 (pt) composição farmacêutica
BR112015013215A2 (pt) proteína slurp-1 para uso na fabricação de medicamentos para o tratamento de doenças oculares
BR112022027124A2 (pt) Formulações para promover a hidratação e métodos de uso das mesmas
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
BR112022023517A2 (pt) Hidrolisado de proteína de torta de sementes de moringa peregrina para sua aplicação como um medicamento, processo para obter o mesmo e composições farmacêuticas e dermatológicas
BR112022001814A2 (pt) Métodos de tratamento de câncer multifocal
Suriadi et al. Case report on the use of a honey on diabetic foot ulcer patients
El-Ghareeb et al. Autoinoculation versus intralesional injection of bleomycin in the treatment of multiple recalcitrant warts
Gallucci et al. Triticum vulgare extract in spray formulation for treatment of vascular ulcers: A case series